FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2525492751> ?p ?o ?g. }

• W2525492751 abstract "During the menopausal transition, women experience a number of symptoms due to declining estrogen levels, including vasomotor symptoms and vulvar and vaginal atrophy (VVA). Unlike vasomotor symptoms, vaginal dryness and dyspareunia, the main symptoms of VVA, typically worsen without treatment and can significantly impact the quality of life. Up to 60% of postmenopausal women may be affected by VVA, but many women unfortunately do not seek treatment due to embarrassment, cardiovascular and oncologic risk factor, or other factors. Therefore, local estrogen treatment is still controversial due to the systemic absorption of estradiol and its potential effects on the breast and endometrium.The fact that up to 26% of women using systemic hormonal therapy continue to experience symptoms of urogenital atrophy is sufficient reason to justify not recommending systemic hormonal therapy in women with vaginal symptoms only; many women initially require a combination of systemic and local estrogen therapy, especially when it is used at low doses.Intravaginal application of DHEA as an alternative treatment compared to local estrogen therapy. Intravaginal DHEA does not increase serum E2 levels and may be a better option for long term treatment of VVA as there is no increase in serum E2 levels with DHEA. Previous data have shown that intravaginal dehydroepiandrosterone (DHEA, prasterone) improved all the domains of sexual function, an effect most likely related to the local formation of androgens from DHEA.As the first non-hormonal alternative to estrogen-based products for this indication, the approval of ospemifene represents a significant milestone in postmenopausal women's health. Ospemifene is a non-steroidal estrogen receptor agonist/antagonist, also known as a selective estrogen receptor modulator (SERM), which seems to be effective in genitourinary symptoms.There is now a new alternative to systemic hormone therapy with estrogen/gestagens. The tissue-selective estrogen complex (TSEC) which combines a SERM (bazedoxifene, BZA) with conjugated equine estrogens (CEE) is designed not only to improve menopausal symptoms but to prevent osteoporosis, while maintaining the benefits of estrogen therapy on vasomotor symptoms and vulvovaginal atrophy, but antagonizing stimulatory effects on the endometrium and mammary gland. The two studied doses of BZA/CEE (20 mg BZA + 0.425 mg CEE and 20 mg BZA + 0.625 mg CEE) have been shown to improve the percentage of superficial cells, reducing the percentage of basal cells. Thus, 20 mg BZA + 0.625 mg CEE reduces the severity of symptoms caused by atrophic vulvovaginitis by 56% and normalizes vaginal histology and pH. This efficacy persists for 2 years.Here we aim to evaluate current experimental and actual clinical strategies to achieve the main therapeutic goal for genitourinary syndrome and VVA in menopause which is the relief of symptoms, a better quality of life and women’ s health in menopausal women not eligible for Hormonal Replacement Therapy (HRT)." @default.
• W2525492751 created "2016-10-07" @default.
• W2525492751 creator A5004083793 @default.
• W2525492751 creator A5050899976 @default.
• W2525492751 creator A5062365078 @default.
• W2525492751 date "2016-09-22" @default.
• W2525492751 modified "2023-09-23" @default.
• W2525492751 title "Impact of new systemic oral and local, hormonal and non-hormonal treatments on genitourinary syndrome and Vulvo-Vaginal-Atrophy (VVA) through the menopausal transition: the right therapy in patients at risk" @default.
• W2525492751 doi "https://doi.org/10.14341/probl201662547-48" @default.
• W2525492751 hasPublicationYear "2016" @default.
• W2525492751 type Work @default.
• W2525492751 sameAs 2525492751 @default.
• W2525492751 citedByCount "0" @default.
• W2525492751 crossrefType "journal-article" @default.
• W2525492751 hasAuthorship W2525492751A5004083793 @default.
• W2525492751 hasAuthorship W2525492751A5050899976 @default.
• W2525492751 hasAuthorship W2525492751A5062365078 @default.
• W2525492751 hasBestOaLocation W25254927512 @default.
• W2525492751 hasConcept C121608353 @default.
• W2525492751 hasConcept C126322002 @default.
• W2525492751 hasConcept C133507102 @default.
• W2525492751 hasConcept C141071460 @default.
• W2525492751 hasConcept C2776214587 @default.
• W2525492751 hasConcept C2776917545 @default.
• W2525492751 hasConcept C2776992908 @default.
• W2525492751 hasConcept C2777164284 @default.
• W2525492751 hasConcept C2777744392 @default.
• W2525492751 hasConcept C2777911890 @default.
• W2525492751 hasConcept C2778311097 @default.
• W2525492751 hasConcept C2778562196 @default.
• W2525492751 hasConcept C2780275930 @default.
• W2525492751 hasConcept C2781172350 @default.
• W2525492751 hasConcept C29456083 @default.
• W2525492751 hasConcept C42407357 @default.
• W2525492751 hasConcept C530470458 @default.
• W2525492751 hasConcept C71315377 @default.
• W2525492751 hasConcept C71924100 @default.
• W2525492751 hasConceptScore W2525492751C121608353 @default.
• W2525492751 hasConceptScore W2525492751C126322002 @default.
• W2525492751 hasConceptScore W2525492751C133507102 @default.
• W2525492751 hasConceptScore W2525492751C141071460 @default.
• W2525492751 hasConceptScore W2525492751C2776214587 @default.
• W2525492751 hasConceptScore W2525492751C2776917545 @default.
• W2525492751 hasConceptScore W2525492751C2776992908 @default.
• W2525492751 hasConceptScore W2525492751C2777164284 @default.
• W2525492751 hasConceptScore W2525492751C2777744392 @default.
• W2525492751 hasConceptScore W2525492751C2777911890 @default.
• W2525492751 hasConceptScore W2525492751C2778311097 @default.
• W2525492751 hasConceptScore W2525492751C2778562196 @default.
• W2525492751 hasConceptScore W2525492751C2780275930 @default.
• W2525492751 hasConceptScore W2525492751C2781172350 @default.
• W2525492751 hasConceptScore W2525492751C29456083 @default.
• W2525492751 hasConceptScore W2525492751C42407357 @default.
• W2525492751 hasConceptScore W2525492751C530470458 @default.
• W2525492751 hasConceptScore W2525492751C71315377 @default.
• W2525492751 hasConceptScore W2525492751C71924100 @default.
• W2525492751 hasLocation W25254927511 @default.
• W2525492751 hasLocation W25254927512 @default.
• W2525492751 hasOpenAccess W2525492751 @default.
• W2525492751 hasPrimaryLocation W25254927511 @default.
• W2525492751 hasRelatedWork W135519663 @default.
• W2525492751 hasRelatedWork W1531968143 @default.
• W2525492751 hasRelatedWork W1966543349 @default.
• W2525492751 hasRelatedWork W1968496407 @default.
• W2525492751 hasRelatedWork W1973186132 @default.
• W2525492751 hasRelatedWork W198890454 @default.
• W2525492751 hasRelatedWork W2005489092 @default.
• W2525492751 hasRelatedWork W2007991289 @default.
• W2525492751 hasRelatedWork W2024018701 @default.
• W2525492751 hasRelatedWork W2031143330 @default.
• W2525492751 hasRelatedWork W2086356273 @default.
• W2525492751 hasRelatedWork W2086895273 @default.
• W2525492751 hasRelatedWork W2117308794 @default.
• W2525492751 hasRelatedWork W2129968228 @default.
• W2525492751 hasRelatedWork W2337599424 @default.
• W2525492751 hasRelatedWork W2411731944 @default.
• W2525492751 hasRelatedWork W3021620231 @default.
• W2525492751 hasRelatedWork W3106663951 @default.
• W2525492751 hasRelatedWork W3132297462 @default.
• W2525492751 hasRelatedWork W42848116 @default.
• W2525492751 isParatext "false" @default.
• W2525492751 isRetracted "false" @default.
• W2525492751 magId "2525492751" @default.
• W2525492751 workType "article" @default.